Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- **LP-Focused Asia PE-VC Summit:** The upcoming Asia PE-VC Summit in 2024 will feature over 35 limited partner (LP) speakers and more than 500 LP attendees from various key markets such as Greater China, the Middle East, North Asia, Europe, and North America.
- **Discounted Event Tickets:** You can save 43% on your ticket to the Asia PE-VC Summit by booking now.
- **Fund Updates:** Kedaara Capital closes its fourth fund at $1.73 billion, and Investcorp launches a $1 billion fund backed by China’s sovereign wealth fund CIC.
- **Impact Investing Shift:** LPs and fund allocators are increasingly focusing on impact management and outcome measurement, signaling a change in investment strategies.
- **Regional Expansion:** Schroders Greencoat looks to expand in Asia, while Next Billion Capital Partners closes the first round of its new $250 million fund for digital investments in Southeast Asia.
- **Mergers and Launches:** Shanghai State-Owned Capital Investment merges with Shanghai S&T Venture Capital, and Shanghai Sci-Tech Innovation Center Capital plans to launch a 10-billion-yuan ($1.4 billion) secondary fund.
- **Industry Moves:** Peak XV Partners’ managing director departs to launch a new investment fund, and 10 VC firms set up new offices in Malaysia.
- **Challenges for Fund Raising:** First-time funds in India face difficulties as LPs reduce funding, with only $15 million raised during Q1 of the year.
- **Healthcare Sector Growth:** India sees significant growth in its healthcare sector, attracting investments such as Temasek’s $2 billion in Manipal Hospitals.
- **Financial Outlook:** Private funding for Southeast Asia-based startups drops to the lowest level in over five years, while logistics startup LetsTransport raises $22 million in a Series E funding round.
APAC Private Markets Research
Explore latest Insights on APAC Private Markets on Smartkarma
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
Also, check out the latest in ECM Research on Smartkarma
